ResearcherMaastricht UniversityActive in the last 2 years
Tom Luedde
Matched on ORCID iD 0000-0002-6288-8821; OpenAlex author ID A5000874547. Sources: OpenAlex.
Their work
- Papers
- 13 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 42
2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 3 papers
Papers 13
- A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Last author DOI 10.1038/s41467-025-56493-7↗
- Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
- A sex dependent association between the history of autoimmune disease and the development of pancreatic cancer: a case-control study of 32,640 patients. Co-author DOI 10.3389/fonc.2025.1613787↗
- Elevated HbA1c Levels Are Associated with a Risk of Pancreatic Cancer: A Case-Control Study. Co-author DOI 10.3390/jcm13185584↗
- N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pancreatic Cancer? Co-author DOI 10.3390/cancers14071834↗
- Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Co-author DOI 10.1016/j.pan.2021.02.024↗
- Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14010068↗
- Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. Co-author DOI 10.3390/jcm10030490↗
- Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-018-38352-2↗
- High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. Last author DOI 10.1093/carcin/bgz033↗
- Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer. Co-author DOI 10.1155/2019/5603474↗
- Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. Co-author DOI 10.3390/jcm7070175↗
- Current and future biomarkers for pancreatic adenocarcinoma. Last author DOI 10.1177/1010428317692231↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christoph Roderburg · 7 shared papers, 2017–2025 · strength 0.95
- Paper A sex dependent association between the history of autoimmune disease and the development of pancreatic cancer: a case-… DOI 10.3389/fonc.2025.1613787↗
- Paper Elevated HbA1c Levels Are Associated with a Risk of Pancreatic Cancer: A Case-Control Study. DOI 10.3390/jcm13185584↗
- Paper Current and future biomarkers for pancreatic adenocarcinoma. DOI 10.1177/1010428317692231↗
- Wolfram Trudo Knoefel · 5 shared papers, 2021–2025 · strength 0.75
- Paper Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. DOI 10.1038/s41598-025-94362-x↗
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7↗
- Paper N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pa… DOI 10.3390/cancers14071834↗
- Sven Heiko Loosen · 6 shared papers, 2017–2025 · strength 0.74
- Paper A sex dependent association between the history of autoimmune disease and the development of pancreatic cancer: a case-… DOI 10.3389/fonc.2025.1613787↗
- Paper Current and future biomarkers for pancreatic adenocarcinoma. DOI 10.1177/1010428317692231↗
- Paper Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer. DOI 10.1155/2019/5603474↗
- Iréne Esposito · 4 shared papers, 2021–2025 · strength 0.56
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7↗
- Paper N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pa… DOI 10.3390/cancers14071834↗
- Paper Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. DOI 10.1016/j.pan.2021.02.024↗
- Karel Kostev · 2 shared papers, 2024–2025 · strength 0.54
- Andreas H. Krieg · 3 shared papers, 2021–2024 · strength 0.49
- Paper Elevated HbA1c Levels Are Associated with a Risk of Pancreatic Cancer: A Case-Control Study. DOI 10.3390/jcm13185584↗
- Paper N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pa… DOI 10.3390/cancers14071834↗
- Paper Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. DOI 10.1016/j.pan.2021.02.024↗
- Sami Alexander Safi · 3 shared papers, 2021–2022 · strength 0.40
- Paper N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pa… DOI 10.3390/cancers14071834↗
- Paper Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. DOI 10.1016/j.pan.2021.02.024↗
- Paper Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreat… DOI 10.3390/cancers14010068↗
- Georg J. Wiltberger · 3 shared papers, 2019–2025 · strength 0.37
- Paper Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. DOI 10.1038/s41598-025-94362-x↗
- Paper Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. DOI 10.3390/jcm10030490↗
- Paper High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after rese… DOI 10.1093/carcin/bgz033↗
- Frederik J. Hansen · 1 shared paper, 2025 · strength 0.33
- Xiuxiang Tan · 2 shared papers, 2021–2025 · strength 0.30
- Lara Rosaline Heij · 2 shared papers, 2021–2025 · strength 0.30
- Shivan Sivakumar · 2 shared papers, 2021–2025 · strength 0.30
- Alexander Rehders · 2 shared papers, 2021 · strength 0.25
- Lena Häberle · 2 shared papers, 2021 · strength 0.25
- Steven Grewe · 1 shared paper, 2024 · strength 0.21
- Edgar Dahl · 1 shared paper, 2025 · strength 0.19
- Evelien J.M. de Jong · 1 shared paper, 2025 · strength 0.19
- Michail Doukas · 1 shared paper, 2025 · strength 0.19
- Bas Groot Koerkamp · 1 shared paper, 2025 · strength 0.19
- Judith de Vos‐Geelen · 1 shared paper, 2025 · strength 0.19
- Casper H.J. van Eijck · 1 shared paper, 2025 · strength 0.19
- Marina Lesina · 1 shared paper, 2025 · strength 0.16
- Anne T. Schneider · 1 shared paper, 2025 · strength 0.16
- Aristeidis Papargyriou · 1 shared paper, 2025 · strength 0.16
- Thilo Hackert · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.